Adaptation of a Behavioral Treatment for Latinos With Panic Disorder/Asthma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Albert Einstein College of Medicine
- Enrollment
- 53
- Locations
- 2
- Primary Endpoint
- Asthma Control Based on Rescue Medication Use
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The research plan involves two aims: 1) Cultural adaptation of the Panic-Asthma Treatment and 2) a randomized, placebo-controlled pilot study. Participants will be primarily recruited from two major, inner-city hospitals in the Bronx, NY. Diagnosis of Panic Disorder (PD) will be based on the Structured Clinical Interview for DSM-IV. Diagnosis of asthma will be based on national guidelines. The first year of the project will be devoted to approximately 5 focus groups with Latino (primarily Puerto Rican) participants, pilot treatment and participant feedback. The protocol will be adapted based on key cultural issues that are systematically observed during Phase 1. During Years 2-3, 40 participants with PD and asthma will be randomized into two treatment arms: Panic-Asthma Treatment and an active placebo condition involving music therapy and paced breathing at resting respiration rates. Each treatment will involve 8 weekly sessions. An interviewer, who will be blind to treatment condition, will conduct assessments at pre-treatment, mid-treatment, post-treatment, and 3-month follow-up. The primary hypotheses are that participants in the Panic-Asthma treatment group will have greater decreases than subjects in the placebo condition on the PD severity scale and albuterol use (i.e., rescue asthma medication) from pre-test to post-test and across 3-month follow-up.
Detailed Description
Asthma and panic disorder (PD) share strikingly similar phenomenology. Respiratory related symptoms, such as dyspnea, dizziness, chest tightness, feelings of choking and sensations of smothering are common in both disorders. The overlap in symptoms between asthma and panic may lead an individual to mistake a panic attack as an asthma attack. In order to better understand this overlap, we hypothesized that participants who received Cognitive Behavioral Psychophysiological Therapy (CBPT) would display greater reductions in PD severity and improvements in asthma control at post- treatment and 3-month follow-up. We predicted that improvements in PD severity in the CBPT group would be mediated by reductions in the perceived physical consequences of anxiety. We selected music therapy and paced breathing at each participant's average respiration rate for the comparison active treatment. Randomized participants will undergo either the CBPT or MRT protocol, be given the same psychological assessments, and have their physiological data collected.
Investigators
Jonathan Feldman
Associate Professor of Psychology
Albert Einstein College of Medicine
Eligibility Criteria
Inclusion Criteria
- •DSM-IV criteria for current PD with or without agoraphobia
- •fluency in spoken English or Spanish
- •no changes in prescribed levels of panicolytic medication for two months prior to the study and no changes in panicolytic medication during the two months of the active protocol
- •history or presence of episodic symptoms of airflow obstruction, namely, wheezing, shortness of breath, chest tightness, or cough
- •airflow obstruction showing FEV1 \< 80% predicted and FEV1/FVC \< 65% or below the lower limit of normal
- •airflow obstruction must be at least partly reversible, as demonstrated by:
- •Positive Bronchodilator test in past year from Medical Chart Review or Baseline session
- •Positive Bronchodilator test during past 10 years (from Medical Chart Review) and asthma symptoms reported past 12 months (from Medical Chart Review or Baseline Questionnaires)
- •Improvement in PEF of ≥20% from Medical Chart Review past 10 years (from Medical Chart Review) and asthma symptoms reported past 12 months (from Medical Chart Review or Baseline Questionnaires)
- •Clinical improvement in asthma symptoms after initiation of anti-inflammatory medication, as documented in medical records.
Exclusion Criteria
- •evidence of active bipolar disorder or psychosis
- •mental retardation or organic brain syndrome
- •current alcohol or substance abuse/dependence
- •foreign body aspiration, vocal cord dysfunction, or other pulmonary diseases
- •history of smoking 20 pack-years or more
- •history consistent with emphysema, sarcoidosis, bronchiectasis, pulmonary tuberculosis, lung cancer, cardiovascular or neurological disease
- •current participation in alternative psychotherapy for anxiety or panic for less than 6 months
Outcomes
Primary Outcomes
Asthma Control Based on Rescue Medication Use
Time Frame: Change from Baseline to Post-Intervention (8 weeks)
Dosers (electronic devices used to monitor the usage of metered-dose inhalers) were attached to participants' asthma rescue inhalers to count the number of puffs of medication used during the treatment period. Use of rescue medication was then coded as good asthma control (less than or equal to rescue medication use twice a week) or poor control (rescue medication use greater than two days a week) in accordance with national guidelines (NHLBI, 2007).
Change in Severity of Panic Disorder as Measured by the Panic Disorder Severity Scale
Time Frame: Baseline, Post-Treatment (end of week 8)
The Panic Disorder Severity Scale (PDSS) is a clinician-administered questionnaire used to assess the severity of panic attacks. The PDSS consists of seven items with each ranging in severity from 0 (none) - 4 (extreme); so total score ranges from 0 to 28.
Clinical Global Impression Scale (CGI)
Time Frame: Change from Baseline to Post-Intervention (8 weeks)
The CGI is a 2-item scale rated by clinicians to assesses for a patient's functioning prior and subsequent to the implementation of an intervention. In the current study, the CGI was used to assess panic disorder illness severity in patients as well as identify whether subjects responded to the study intervention. The CGI scale includes a question on level of improvement subsequent to intervention ranging from 1 (very much improved) to 7 (very much worse), and a question on severity of illness ranging from 1 (normal) to 6 (among the most extremely ill of patients). To be a treatment responder, a participant had to have a score of 2 (much improved) or better and be rated as a 3 (mild) or less on their illness severity.
Secondary Outcomes
- Asthma Control Questionnaire (ACQ)(Change from Baseline to Post-Intervention (8 weeks))
- Medication Adherence Report Scale (Adherence to Controller Medications for Asthma)(Change from Baseline to Post-Intervention (8 weeks))